Table 4.
Dynamic of HIV DNA and cell-associated RNA levels in CD4 T-cells isolated from blood and semen during cannabinoids treatment.
| HIV DNA and RNA | Study Timeline | ||||||
|---|---|---|---|---|---|---|---|
| Week 0 Treatment Initiation n = 10 |
Week 1 n = 10 |
Week 2 n = 10 |
$ Week 6 n = 9 |
$ Week 8 n = 8 |
$ Week 12 End of Treatment n = 8 |
$ Week 14 Study Termination n = 8 |
|
| Total HIV DNA (copies/106 CD4) [Mean (SD)] |
1016 (1081) | 908.1 (817.3) | 920.4 (816.5) | 1053 (1121) | 1292 (1310) | 979.1 (1015) | 1143 (1318) |
| [Median (IQR)] | 708.1 (125.1–1679) | 765.3 (239.3–1449) | 819.8 (176.2–1529) | 911.9 (141- 1886) | 790.3 (165.6–2843) | 629.9 (155.5–2156) | 658.5 (152.3–2317) |
| LTR-gag cell-associated RNA (copies/106 CD4) [Mean (SD)] |
493.5 (557.3) | 593.9 (817.3) i | 529.2 (630.3) | 476.3 (479.6) | 1370 (1687) i,s | 572.9 (752.8) s | 751.9 (858.3) |
| [Median (IQR)] | 308.8 (4.9–915.8) | 224.3 (3.5–1088) i | 271.2 (13.4–1081) | 281.1 (21.9–938.8) | 142 (10.1–3151) i,s | 283.9 (2.1–1290) s | 386.9 (26.0–1770) |
| RNA/DNA ratio [Mean (SD)] |
0.47 (0.45) | 0.56 (0.55) | 0.43 (0.41) | 0.43 (0.37) | 0.62 (0.62) s | 0.44 (0.53) s | 1.85 (3.53) |
| [Median (IQR)] | 0.3 (0.2–1.0) | 0.46 (0.08–0.87) | 0.37 (0.08–0.76) | 0.33 (0.12–0.84) | 0.44 (0.05–1.26) s | 0.17 (0.01–1.07) s | 0.50 (0.28–1.54) |
Results are shown as the mean and standard deviation (SD) and as the median and interquartile range (IQR). Significant differences (p < 0.05) following the Wilcoxon matched-pairs signed-rank test are mentioned as follows: a: week 0 vs. week 1; b: week 0 vs. week 2; c: week 0 vs. week 6; d: week 0 vs. week 8; e: week 0 vs. week 12; f: week 0 vs. week 14; g: week 1 vs. week 2; h: week 1 vs. week 6; i: week 1 vs. week 8; j: week 1 vs. week 12; k: week 1 vs. week 14; l: week 2 vs. week 6; m: week 2 vs. week 8; n: week 2 vs. week 12; o: week 2 vs. week 14; p: week 6 vs. week 8; q: week 6 vs. week 12; r: week 6 vs. week 14; s: week 8 vs. week 12; t: week 8 vs. week 14; u: week 12 vs. week 14. Significant values are presented in bold. $: Two participants from CBD-only were excluded from analyses at week 6 (one participant) and weeks 8, 12, and 14 (two participants) because they were withdrawn at week 6 for safety concerns.